B-cell ALL in England: Clinical Outcomes and Healthcare Resource Use
Research type
Research Study
Full title
The English Ball Study - Clinical Outcomes and Healthcare Resource Use in B-cell ALL in England
IRAS ID
273134
Contact name
Adrian Paul Rabe
Contact email
Sponsor organisation
Health iQ
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
B-cell Acute lymphoblastic leukaemia (B-cell ALL) is a cancer involving specific types of white blood cells. Normal white blood cells function to protect the body as part of the immune system. In B-cell ALL, these cells have mutated and now invade and harm different parts of the body. Being a very debilitating disease, it is important to understand how much resources they use up in the national health service, as well as the various treatments they undergo, and how those treatments impact their survival. This study aims to use anonymized and pseudonymized data from Public Health England to construct a group of patients with B-cell ALL. Using the same dataset linked to secondary care and to the cancer treatment dataset, the study would determine healthcare resource use and treatment pathways, as well as clinical outcomes. The span of time covered would be from 2006 to the latest available data when it would be requested. Once completed, this study would hopefully inform health policy to reduce healthcare resources and reconfigure services to provide better treatment pathways for patients.
REC name
West of Scotland REC 5
REC reference
19/WS/0158
Date of REC Opinion
10 Oct 2019
REC opinion
Further Information Favourable Opinion